Stevanato Group SpA (STVN)

Currency in USD
13.57
+0.36(+2.73%)
Closed·
13.570.00(0.00%)
·
STVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
12.8513.65
52 wk Range
12.0525.45
Key Statistics
Prev. Close
13.57
Open
13.23
Day's Range
12.85-13.65
52 wk Range
12.05-25.45
Volume
1.37M
Average Volume (3m)
589.85K
1-Year Change
-43.6929%
Book Value / Share
6.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
STVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.96
Upside
+47.08%
Members' Sentiments
Bearish
Bullish
ProTips
7 analysts have revised their earnings downwards for the upcoming period

Stevanato Group SpA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

9 Buy
4 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 19.96
(+47.08% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Hold16.00+17.91%23.00MaintainNov 04, 2026
William Blair
Hold---DowngradeNov 04, 2026
Citi
Buy20.00+47.38%26.00MaintainNov 03, 2026
Deutsche Bank
Hold22.00+62.12%-New CoverageOct 07, 2026
UBS
Hold---New CoverageSep 09, 2026

Stevanato Group SpA Earnings Call Summary for Q3/2026

  • Q3 revenue rose 8% to €326.1M, beating estimates; adjusted EPS of €0.16 matched forecasts; shares plunged 24% to $14.97 on 2027 outlook concerns.
  • Management warned 2027 growth will slow to low single digits due to temporary GLP-1 syringe volume decline from one customer, down from historical targets.
  • High-value solutions reached 46% of revenue; adjusted EBITDA margin expanded 150bps to 27.2%, reflecting strategic shift toward more profitable products.
  • Full-year 2026 guidance reiterated: revenue €1.26B-€1.28B, adjusted EBITDA €335M-€345.2M, and adjusted EPS €0.60-€0.62 despite engineering segment weakness.
  • Company backfilling lost GLP-1 volumes with other biologics (up 30% in Q3); Alina pen injector launch and Fishers facility ramp-up expected to drive future growth.
Last Updated: 2026-11-03, 09:54 a/m
Read Full Transcript

Earnings

Latest Release
Nov 03, 2026
EPS / Forecast
0.16 / 0.16
Revenue / Forecast
326.1M / 320.95M
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.58
Dividend Yield
0.46%
Industry Median 1.43%
Annualized payout
0.06
Paid annually
5-Years Growth
-79.83%
Growth Streak

STVN Income Statement

Compare STVN to Peers and Sector

Metrics to compare
STVN
Peers
Sector
Relationship
P/E Ratio
23.7x−0.2x−0.2x
PEG Ratio
-0.100.00
Price/Book
2.1x1.1x2.6x
Price / LTM Sales
2.7x0.7x2.8x
Upside (Analyst Target)
47.1%5.7%65.6%
Fair Value Upside
Unlock4.9%10.0%Unlock

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
22.06M8.08%296.45M
Other Institutional Investors
249.28M91.27%3.35B
Public Companies & Retail Investors
1.78M0.65%23.98M
Total
273.13M100.00%3.67B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Stevanato Holding S.R.L.81.75%223,293,9763,001,071
Conestoga Capital Advisors, LLC2.57%7,007,61394,182

People Also Watch

101.0000
PRY
+0.80%
5.7000
TLIT
-1.06%
43.7300
GASI
-1.86%
6.6400
CPRI
-1.63%
6.1770
ISP
-1.40%

FAQ

What Is the Stevanato Group SpA (STVN) Stock Price Today?

The Stevanato Group SpA stock price today is 13.57 USD.

What Stock Exchange Does Stevanato Group SpA Trade On?

Stevanato Group SpA is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Stevanato Group SpA?

The stock symbol for Stevanato Group SpA is "STVN."

Does Stevanato Group SpA Pay Dividends? What’s The Current Dividend Yield?

The Stevanato Group SpA dividend yield is 0.5%%.

What Is the Stevanato Group SpA Market Cap?

As of today, Stevanato Group SpA market cap is 3.61B USD.

What Is Stevanato Group SpA's Earnings Per Share (TTM)?

The Stevanato Group SpA EPS (TTM) is 0.58.

When Is the Next Stevanato Group SpA Earnings Date?

Stevanato Group SpA will release its next earnings report on Mar 11, 2027.

From a Technical Analysis Perspective, Is STVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Stevanato Group SpA Stock Split?

Stevanato Group SpA has split 0 times.

How Many Employees Does Stevanato Group SpA Have?

Stevanato Group SpA has 6010 employees.

What is the current trading status of Stevanato Group SpA (STVN)?

As of Nov 07, 2026, Stevanato Group SpA (STVN) is trading at a price of 13.57 USD, with a previous close of 13.57 USD. The stock has fluctuated within a day range of 12.85 USD to 13.65 USD, while its 52-week range spans from 12.05 USD to 25.45 USD.

What Is Stevanato Group SpA (STVN) Price Target According to Analysts?

The average 12-month price target for Stevanato Group SpA is 19.96 USD, with a high estimate of 26 USD and a low estimate of 16 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +47.08% Upside potential.

What Is the STVN Premarket Price?

STVN's last pre-market stock price is 13.51 USD. The pre-market share volume is 250.00, and the stock has decreased by 0.30, or 2.27%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.